Sanofi-Aventis U.S. LLC (United States) holds 1 active US FDA Type II Drug Master File and 2 inactive and has DMF or CEP filings on record for 3 active ingredients. 29 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “Sanofi-Aventis U.S. LLC: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/sanofi-aventis-u-s-llc

Overview

Sanofi-Aventis U.S. LLC is the U.S. subsidiary of Sanofi, a multinational pharmaceutical company headquartered in Paris, France. The company is engaged in the research, development, manufacturing, and marketing of healthcare products, with a strong emphasis on innovative solutions in various therapeutic areas.

Therapeutic areas

Active ingredients with DMF or CEP filings

Substances for which Sanofi-Aventis U.S. LLC holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.

API / Drug Master Files

Sanofi-Aventis U.S. LLC holds 1 active (3 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.

  • MEGLUMINE ANTIMONIATE (GLUCANTIME)Active2021-10-27
  • EPLIVANSERIN HEMIFUMARATEInactive2008-07-18
  • MDL 101,731Inactive1995-03-28

FDA compliance signals

29 FDA enforcement records linked to this company.

  • recall — Class II2023-05-24

    Lack of Assurance of Sterility: Malformed crimped collar seal

  • recall — Class II2020-08-26

    Failed Stability Specifications: Out of Specification result for enzyme activity levels noted during routine stability testing.

  • recall — Class II2019-12-11

    CGMP Deviations: Presence of NDMA impurity detected in product.

  • recall — Class II2019-12-11

    CGMP Deviations: Presence of NDMA impurity detected in product.

  • recall — Class II2019-12-11

    CGMP Deviations: Presence of NDMA impurity detected in product.

  • recall — Class II2019-12-11

    CGMP Deviations: Presence of NDMA impurity detected in product.

  • recall — Class II2019-12-11

    CGMP Deviations: Presence of NDMA impurity detected in product.

  • recall — Class II2019-12-11

    CGMP Deviations: Presence of NDMA impurity detected in product.

  • recall — Class II2019-12-11

    CGMP Deviations: Presence of NDMA impurity detected in product.

  • recall — Class II2019-12-11

    CGMP Deviations: Presence of NDMA impurity detected in product.

  • recall — Class II2019-12-11

    CGMP Deviations: Presence of NDMA impurity detected in product.

  • recall — Class II2019-12-11

    CGMP Deviations: Presence of NDMA impurity detected in product.

  • recall — Class II2019-12-11

    CGMP Deviations: Presence of NDMA impurity detected in product.

  • recall — Class II2019-12-11

    CGMP Deviations: Presence of NDMA impurity detected in product.

  • recall — Class II2018-07-18

    Temperature Abuse: Product samples of Admelog may not have been shipped at proper temperature.

  • recall — Class II2018-05-09

    Superpotent drug: over-concentrated vials of Docetaxel injection concentrate 20 mg/mL may have been distributed.

  • recall — Class III2018-01-17

    Labeling: Label Error on Declared Strength. A single syringe labeled as 150 mg/1.0 mL was found packaged in a blister labeled as 120 mg/mL

  • recall — Class III2017-11-08

    Labeling: Incorrect or Missing Package Insert: authorized generic product was packaged with the incorrect insert for the brand name product Clolar (clofarabine) injection.

  • recall — Class III2017-07-05

    Superpotent Drug: high out-of-specification result for magnesium.

  • recall — Class III2017-05-17

    Labeling: Incorrect or Missing Package Insert

  • recall — Class I2016-06-01

    Defective Delivery System; potential to have inaccurate dosage delivery

  • recall — Class I2016-06-01

    Defective Delivery System; potential to have inaccurate dosage delivery

  • recall — Class II2012-07-11

    CGMP Deviations: Eloxatin was manufactured by Ben Venue Laboratories, a contract manufacturer, which was recently inspected by the agency and revealed significant issues in Good Manufacturing Practices.

  • recall — Class II2012-07-11

    CGMP Deviations: Eloxatin was manufactured by Ben Venue Laboratories, a contract manufacturer, which was recently inspected by the agency and revealed significant issues in Good Manufacturing Practices.

  • 4832012-03-14

    Written Procedures Not Followed

  • 4832012-03-14

    Changes to Procedures Not Reviewed, Approved

  • 4832012-03-14

    Distribution of oldest stock first

  • 4832012-03-14

    SOPs not followed / documented

  • 4832010-08-18

    Deviations of production time limits

For suppliers

Is this Sanofi-Aventis U.S. LLC?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.